Swelling

Tactile Medical to Release Fourth Quarter and Fiscal Year 2019 Financial Results on February 26, 2020

Retrieved on: 
Wednesday, February 5, 2020
Medicine, Chronic venous insufficiency, Lymphedema, Insufficiency, Swelling, Venous insufficiency, Medical specialties, Clinical medicine, Tactile

MINNEAPOLIS, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (Tactile Medical) (Nasdaq:TCMD), a medical technology company focused on developing medical devices for the treatment of chronic diseases at home, today announced that fourth quarter and fiscal year 2019 financial results will be released after the market closes on Wednesday, February 26.

Key Points: 
  • MINNEAPOLIS, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (Tactile Medical) (Nasdaq:TCMD), a medical technology company focused on developing medical devices for the treatment of chronic diseases at home, today announced that fourth quarter and fiscal year 2019 financial results will be released after the market closes on Wednesday, February 26.
  • Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13698949.
  • Tactile Medical is a leader in developing and marketing at-home therapy devices that treat chronic swelling conditions such as lymphedema and chronic venous insufficiency.
  • Tactile Medical takes pride in the fact that our solutions help increase clinical efficacy, reduce overall healthcare costs and improve the quality of life for patients with chronic conditions.

Integrated Clinical Trial Analyses Further Substantiate that Teprotumumab Significantly Improves Debilitating Effects of Thyroid Eye Disease, Including Eye Bulging, Double Vision and Quality of Life

Retrieved on: 
Thursday, October 31, 2019
FDA, Health, Pharmaceutical, Optical, Clinical trials, Articles, Health, Medicine, Hoffmann-La Roche, Teprotumumab, Exophthalmos, Quality of life, Swelling, Thyroid Eye Disease, Teprotumumab, Horizon

The results support prior analyses of significant reductions in inflammation, proptosis (eye bulging) and diplopia (double vision), as well as improvements in quality of life (QoL).

Key Points: 
  • The results support prior analyses of significant reductions in inflammation, proptosis (eye bulging) and diplopia (double vision), as well as improvements in quality of life (QoL).
  • The GO-QoL scale consists of two subscales to evaluate the quality of life of patients with TED (Graves Ophthalmology), including impacts on visual function and self-assessment of appearance.
  • CAS is a scale used to assess the disease activity of TED, and measures the degree of inflammation, including pain, swelling and redness.
  • Horizon is also conducting the OPTICX extension trial to gather further insight into the long-term efficacy and safety of teprotumumab.

American Society of Breast Surgeons: Innovative Lymphedema Surveillance Program and Early Intervention Significantly Help Prevent Progression

Retrieved on: 
Thursday, May 2, 2019
Women, Surgery, Health, Clinical trials, Medical devices, Oncology, Radiology, Research, Other Science, Consumer, Science, Organ systems, Medicine, Medical specialties, RTT, Lymphedema, Lymph node, Breast cancer, Radiation therapy, Swelling, Cancer, Secondary lymphedema, Lymphangiosarcoma

Surveillance of women at risk for breast cancer-related lymphedema using bioimpedance spectroscopy (BIS) was more effective in preventing lymphedema progression than traditional arm circumference measurement, when each is combined with immediate compression therapy.

Key Points: 
  • Surveillance of women at risk for breast cancer-related lymphedema using bioimpedance spectroscopy (BIS) was more effective in preventing lymphedema progression than traditional arm circumference measurement, when each is combined with immediate compression therapy.
  • They were presented this week at the annual meeting of the American Society of Breast Surgeons.
  • Breast cancer-related lymphedema is a chronic, debilitating swelling of the arm that may result from surgery, radiation, or chemotherapy affecting the lymph nodes.
  • Lymphedema significantly lowers quality-of-life and consistently ranks as the number one fear of breast cancer survivors, says lead study author Sheila Ridner, PhD, RN, FAAN, Vanderbilt University School of Nursing.

medi USA introduces the new circaid® juxtalite® hd

Retrieved on: 
Tuesday, January 15, 2019
Medicine, Medical signs, Swelling, Ulcer, Edema

WHITSETT, N.C., Jan. 15, 2019 /PRNewswire/ -- Medical device manufacturer medi USA announced the launch of its new ready-to-wear circaid juxtalite hd.

Key Points: 
  • WHITSETT, N.C., Jan. 15, 2019 /PRNewswire/ -- Medical device manufacturer medi USA announced the launch of its new ready-to-wear circaid juxtalite hd.
  • The juxtalite hd comes with a pair of new circaid compressive undersocks, which apply compression to the foot and ankle areas to effectively manage foot and ankle swelling.
  • medi also offers the circaid juxtalite as a venous disease & ulcer compression solution for patients with mild edema.
  • The new ready-to-wear juxtalite hd joins a full range of compression products offered by medi in its circaid inelastic compression line.